A Comparison of Mohs Micrographic Surgery and Wide Excision for the Treatment of Atypical Fibroxanthoma : Dermatologic Surgery

Secondary Logo

Journal Logo

ORIGINAL ARTICLES: PDF Only

A Comparison of Mohs Micrographic Surgery and Wide Excision for the Treatment of Atypical Fibroxanthoma

DAVIS, JAIME L. MD1; RANDLE, HENRY W. MD, PhD1; ZALLA, MARK J. MD1; ROENIGK, RANDALL K. MD1; BRODLAND, DAVID G. MD1

Author Information
Dermatologic Surgery 23(2):p 105-110, February 1997. | DOI: 10.1111/j.1524-4725.1997.tb00670.x

Abstract

background 

Atypical fibroxanthoma (AFX) is an uncommon spindle cell neoplasm occurring most often in actinically damaged skin of elderly patients. This tumor has invasive potential, may recur locally after excision, and rarely metastasizes. To conserve tissue and improve the likelihood of cure, Mohs micro–graphic surgery (MMS) has been used for treatment.

objective 

We review and discuss the Mayo Clinic experience treating AFX with MMS and retrospectively compare the clinical outcome with that in a similar cohort of patients treated with wide local excision (WE).

methods 

The medical records of 45 patients were reviewed at three Mayo Clinic practices. Follow–up data were available for 44 patients: 19 treated with MMS and 25 with WE.

results 

In patients treated with MMS, there were no recurrences after a mean follow–up of 29.6 months. There were three first recurrences in 25 patients (12%) treated with WE after a mean follow–up of 73.6 months. One patient had a single local recurrence, and two patients each had two local recurrences. Parotid node metastasis eventually developed in one of the patients with two local recurrences, so that the regional metastatic rate in this series was 4% (1 in 25 patients).

conclusion 

Microscopic control of the surgical margins with MMS in the treatment of AFX results in a lower recurrence rate than that with WE and conserves normal tissue.

© 1997 by the American Society for Dermatologic Surgery, Inc.

You can read the full text of this article if you:

Access through Ovid